65,437 trials
Type 2 Diabetes Mellitus · Myocardial Fibrosis · Myocardial Inflammation
Primary: Extracellular Volume Fraction (ECV) — 28.5; 27.7; 28.7; 28.4 Percentage of total tissue volume — p=< 0 .0125
Type 2 Diabetes
Primary: Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline — -2.43; 0.44 percentage — p=<0.024
Metastatic Malignant Neoplasm in the Bone · Metastatic Malignant Neoplasm in the Lung · Salivary Gland Carcinoma
Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 — 3; 1; 2; 6 Participants
Mechanical Ventilation Complication · Acute Respiratory Failure · Intubation Complication
Primary: Reintubation — 57; 52 Participants
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Maximum Plasma Concentration (Cmax) for SI-722 — NA; NA; NA; NA ng/mL
Parkinson's Disease
Primary: Motor Function - Objective — 0.93 score on a scale
Coronary Artery Disease
Primary: Primary Composite (Number) of Deaths / MIs / Invasive Coronary Angiography Without Obstructive Disease — 44; 118; 18; 12 number of events — p=<.001
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Metformin — 3627.171; 4076.521; 6981.833; 6564.938…
Congenital Bleeding Disorder · Haemophilia B
Primary: Number of Participants With Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) (50 Exposure Days) — 2; 0 Participants
Acute Lymphoblastic Leukemia
Primary: Incidence of Adverse Events (AEs) (Safety and Tolerability) — 74; 74; 72; 27 Participants
Cystic Fibrosis
Primary: Feasibility of Participants Completing 2-week Study Visit — 25; 25; 0 Participants
Non-Erosive Gastro-Esophageal Reflux Disease · Heartburn
Primary: Percentage of Days Without Daytime or Nighttime Heartburn — 27.7; 44.8; 44.4 Percentage of days — p=<0.0001
DENT IMPLANTS · LASER
Primary: Mean Probing Pocket Depth — 4.62; 4.45 millimeters
Post Operative Pain Control
Primary: Overall Benefit Analgesia Score — 4; 5; 3; 3 score on a scale — p=0.75
Alzheimer Disease · Dementia · Brain Diseases
Primary: Change in Caregiver Mastery — 12.6; 13; 13 units on a scale